Aquestive Therapeutics vs Tonix Pharmaceuticals
AQST and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AQST and TNXP compare
Aquestive Therapeutics is the larger company, worth 9.5 times as much as Tonix Pharmaceuticals ($491M against $51.6M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus 12.5% for Aquestive Therapeutics).
Aquestive Therapeutics keeps more of each dollar of sales as profit, with a net margin of −162% compared with −420% at Tonix Pharmaceuticals.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 3 for Aquestive Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AQST | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $491M | $51.6M |
| Share price | $3.91 | $3.01 |
| Change, 1 year | −29.9% | −83.0% |
| Change, 5 years | −34.5% | −100.0% |
| Beta (5Y) | 1.45 | 2.01 |
| Employees | 147 | 142 |
| StockData Score | ||
| Total score | 3 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 | 2 |
| Performance score | 0 | 0 |
| Health score | 1 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.0× | 1.2× (better) |
| P/B | – | 0.3× |
| FCF yield | −8.3% (better) | −329% |
| Fair value | – | $18.27 |
| Margin of safety | – | 83.5% |
| Growth | ||
| Revenue growth (TTM) | 12.5% | 318% (better) |
| Revenue growth, 5Y average | −0.58% | – |
| Profitability | ||
| Gross margin | 65.3% | 89.3% (better) |
| Operating margin | −114% (better) | −436% |
| Net margin | −162% (better) | −420% |
| FCF margin | −83.3% (better) | −395% |
| Return on equity | – | −84.1% |
| Return on invested capital | – | −388% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −5.4× | – |
| Current ratio | 6.12 (better) | 4.57 |
| Altman Z-score | −4.49 (better) | −6.62 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −288% |
| Shareholder yield | 0.00% (better) | −288% |
| Ownership | ||
| Held by institutions | 57.4% | 54.6% |
| Held by insiders | 3.2% | 0.27% |
| Insider net buying, 12 months | −$2.3M | $479K (better) |
| Short interest, % of float | 24.1% | 19.4% |
Go deeper
- AQST stock overview
- AQST income statement
- AQST valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.